News articles about RadNet (NASDAQ:RDNT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. RadNet earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 45.0745258535222 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Analyzing RadNet (NASDAQ:RDNT) & Enzo Biochem (ENZ) (americanbankingnews.com)
- Zacks: Analysts Anticipate RadNet, Inc. (RDNT) Will Announce Quarterly Sales of $226.64 Million (americanbankingnews.com)
- RadNet, Inc. Announces Date of its Second Quarter 2017 Financial Results Conference Call (feeds.benzinga.com)
- Reviewing RadNet (RDNT) & Enzo Biochem (ENZ) (americanbankingnews.com)
- Brokerages Expect RadNet, Inc. (RDNT) to Post $0.14 EPS (americanbankingnews.com)
RadNet (RDNT) remained flat at $7.75 on Friday. The company’s stock had a trading volume of 142,353 shares. The stock’s 50 day moving average is $7.66 and its 200 day moving average is $6.56. The firm has a market capitalization of $365.92 million, a price-to-earnings ratio of 50.32 and a beta of 1.01. RadNet has a 52-week low of $5.25 and a 52-week high of $7.98.
RadNet (NASDAQ:RDNT) last issued its quarterly earnings results on Wednesday, May 10th. The medical research company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). RadNet had a return on equity of 19.20% and a net margin of 0.86%. The firm had revenue of $229 million for the quarter, compared to analysts’ expectations of $223.50 million. During the same quarter in the prior year, the firm earned ($0.04) EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Analysts expect that RadNet will post $0.24 EPS for the current year.
Separately, Zacks Investment Research raised RadNet from a “sell” rating to a “hold” rating in a report on Wednesday, May 17th.
ILLEGAL ACTIVITY NOTICE: “RadNet (NASDAQ:RDNT) Earning Somewhat Favorable News Coverage, Report Shows” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2017/07/29/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-radnet-nasdaqrdnt-stock-price-updated.html.
In other news, insider Norman R. Hames sold 8,074 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $7.60, for a total transaction of $61,362.40. Following the transaction, the insider now owns 413,157 shares of the company’s stock, valued at approximately $3,139,993.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Norman R. Hames sold 20,000 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $7.05, for a total value of $141,000.00. Following the transaction, the insider now directly owns 586,203 shares in the company, valued at approximately $4,132,731.15. The disclosure for this sale can be found here. Insiders have sold a total of 262,838 shares of company stock worth $1,955,532 in the last ninety days. Insiders own 9.36% of the company’s stock.
About RadNet
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
